New Therapeutic Options Enhance Breast Cancer Treatment: ASCO Reports
Three Cancer Centers Test Targeted Therapy For Resistant Acute Myelogenous Leukemia
Five-Year Course of Tamoxifen Remains Standard Treatment In HR+ Breast Cancer
Study Finds No Link Between Pill And Breast Cancer Risk
Vasectomy Doesn’t Increase Prostate Cancer Risk
Drug Slows Tumor Growth In Metastatic Kidney Cancer
STI-571 Effects Are Lasting Against GI Stromal Tumors
Monoclonal Antibody Improves AML Response To Therapy
Protocols Approved During the Month of June 2002
Trending Stories
- Richard Pazdur left FDA to avoid being part of “the destruction of the American medical system”
- Pediatric cancer five-year survival rate has increased dramatically, AACR says in inaugural Pediatric Cancer Progress Report
- In first NCAB director’s report, Anthony Letai focuses on centralized grant review, budget outlook
- Antonio Wolff, Mikala Egeblad named co-directors of Johns Hopkins Kimmel Cancer Center Breast and Gynecologic Cancer Program
- Pazdur leaves FDA after 25-year career that shaped the agency’s oncology regulations
BIO calls for the end of “constant turmoil,” urges the administration to “right the ship” - Anthony Letai pledges to ensure stability for extramural and intramural cancer science









